Altre lingue Spero Therapeutics, Inc.

Azioni

SPRO

US84833T1034

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 26/04/2024			Variaz. 5gg	Var. 1 gen.
1,46 ^USD	+2,10%		+4,29%	-0,68%

13/03	Transcript : Spero Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024
13/03	Spero Therapeutics, Inc. riporta i risultati degli utili per il quarto trimestre conclusosi il 31 dicembre 2023	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Spero Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	13/03
Earnings Flash (SPRO) SPERO THERAPEUTICS Reports Q4 Revenue $73.5M, vs. Street Est of $18.6M	13/03
Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update	13/03
Spero Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	13/03
Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024	06/03
Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections	28/02
Spero Therapeutics to Present at Cowen’s 44th Annual Healthcare Conference	26/02
Tamara Joseph Steps Down as Chief Legal Officer and Corporate Secretary of Spero Therapeutics, Inc, Effective as of March 6, 2024	09/02
Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	31/01
Spero Therapeutics Says It Has Enough Funds to Continue Operations Into Late 2025	05/01
Spero Therapeutics Provides Corporate Update and 2024 Outlook	05/01
Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	02/01
Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections	02/01
Earnings Flash (SPRO) SPERO THERAPEUTICS Posts Q3 Revenue $25.5M, vs. Street Est of $15M	13/11
Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update	13/11
Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023	06/11
SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm	03/11
Spero Therapeutics to Present at Upcoming November Investor Conferences	01/11
Spero Therapeutics Appoints Esther Rajavelu Chief Financial Officer	01/11

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Spero Therapeutics, Inc.

Azioni

SPRO

US84833T1034

Altre lingue

Filtri